EA202091989A1 - Способы лечения язвенного колита - Google Patents

Способы лечения язвенного колита

Info

Publication number
EA202091989A1
EA202091989A1 EA202091989A EA202091989A EA202091989A1 EA 202091989 A1 EA202091989 A1 EA 202091989A1 EA 202091989 A EA202091989 A EA 202091989A EA 202091989 A EA202091989 A EA 202091989A EA 202091989 A1 EA202091989 A1 EA 202091989A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
ulcer
methods
disease
invention generally
Prior art date
Application number
EA202091989A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс Бенедикт Канаван
Стюарт Уильям Фридрих
Катрин Энн Крюгер
Кейтрин Мильх
Джей Лоуренс Таттл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202091989A1 publication Critical patent/EA202091989A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA202091989A 2018-03-30 2019-03-28 Способы лечения язвенного колита EA202091989A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
EA202091989A1 true EA202091989A1 (ru) 2021-01-13

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091989A EA202091989A1 (ru) 2018-03-30 2019-03-28 Способы лечения язвенного колита

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI4327866T3 (https=)
HR (2) HRP20260275T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT3773715T (https=)
MA (2) MA52216B1 (https=)
MD (2) MD4327866T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL4327866T3 (https=)
PT (2) PT4327866T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (2) SI3773715T1 (https=)
TW (2) TWI744617B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
AU2023383916A1 (en) * 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202500184A (zh) 2023-03-10 2025-01-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2452694T1 (sl) * 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Also Published As

Publication number Publication date
SI4327866T1 (sl) 2026-04-30
MA52216A (fr) 2021-02-17
MX2020010269A (es) 2020-11-06
RS67806B1 (sr) 2026-03-31
PT3773715T (pt) 2024-05-27
LT4327866T (lt) 2026-03-10
WO2019191464A1 (en) 2019-10-03
US12152072B2 (en) 2024-11-26
AU2023248103B2 (en) 2026-02-05
HRP20240904T1 (hr) 2024-10-11
ES2983809T3 (es) 2024-10-24
TWI744617B (zh) 2021-11-01
CA3095297A1 (en) 2019-10-03
HRP20260275T1 (hr) 2026-04-10
DK4327866T3 (da) 2026-02-23
ES3063700T3 (en) 2026-04-20
NZ767902A (en) 2024-05-31
IL277514B2 (en) 2024-11-01
MY202368A (en) 2024-04-24
JP2025020134A (ja) 2025-02-12
SI3773715T1 (sl) 2024-06-28
JP2022169562A (ja) 2022-11-09
ZA202005388B (en) 2025-05-28
MD3773715T2 (ro) 2024-10-31
US20250034243A1 (en) 2025-01-30
LT3773715T (lt) 2024-06-25
FI3773715T3 (fi) 2024-05-30
SG11202009526RA (en) 2020-10-29
MA52216B1 (fr) 2024-07-31
MD4327866T2 (ro) 2026-04-30
PL3773715T3 (pl) 2024-08-19
JP7331219B2 (ja) 2023-08-22
US20210032325A1 (en) 2021-02-04
AU2023248103A1 (en) 2023-11-09
BR112020018099A2 (pt) 2020-12-22
IL312807B1 (en) 2025-02-01
PL4327866T3 (pl) 2026-04-20
TW201946657A (zh) 2019-12-16
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
JP2023166388A (ja) 2023-11-21
JP2021517156A (ja) 2021-07-15
IL312807A (en) 2024-07-01
DK3773715T3 (da) 2024-05-27
MA67901B1 (fr) 2026-02-27
RS65661B1 (sr) 2024-07-31
IL277514B1 (en) 2024-07-01
UA128578C2 (uk) 2024-08-21
KR102552693B1 (ko) 2023-07-07
EP3773715A1 (en) 2021-02-17
AU2019243283B2 (en) 2023-07-27
PT4327866T (pt) 2026-02-17
HUE067445T2 (hu) 2024-10-28
AU2019243283A1 (en) 2020-09-24
JP7571225B2 (ja) 2024-10-22
IL312807B2 (en) 2025-06-01
FI4327866T3 (fi) 2026-02-18
JP7119114B2 (ja) 2022-08-16
IL277514A (en) 2020-11-30
TWI837532B (zh) 2024-04-01
EP3773715B1 (en) 2024-05-08
EP4327866A3 (en) 2024-03-20
CN111936165A (zh) 2020-11-13
KR20200128101A (ko) 2020-11-11
AU2019243283C1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
EA202091989A1 (ru) Способы лечения язвенного колита
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
EA202091540A1 (ru) Антитела к lilrb2
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201691991A1 (ru) Мультиспецифические антитела
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX382129B (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso.
MX370807B (es) Anticuerpos que se unen a axl.
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
TWD173737S (zh) 肌肉鍛鍊機器
MX2021010460A (es) Metodo de tratamiento con tradipitant.
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
AR105335A1 (es) Anticuerpos monoclonales anti-sortilina
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)